Randomized trial of patients with high-risk #endometrialcancer (n=1095) did not find improvement in disease-free survival from adding #pembrolizumab to postoperative adjuvant treatment (HR 1.02, 95% CI 0.79-1.32, p=.57). Pembrolizumab was associated with better survival (HR 0.31, 95% CI 0.14-0.69) for patients with MMR deficient tumors (n=281). #gyncsm@Annals_Oncologyannalsofoncology.org/article…
Today at the @RivkinCenter AACR Ovarian Cancer Research Symposium Moffitt’s Karen Lu, MD (@karenluMD) co-chairs the Prevention, Early Detection, & Interception session. Check out her video to learn more!
⏰: 9/20 -4:50 p.m. PDT
📍: Washington Ballroom
Learn more ➡️ bit.ly/47E4WlK
Excited to represent @SGO_org@GYNCancer as Social Media Ambassador for our 2025 Annual #SGOMtg! ⏰ Abstract submission deadline is approaching quickly Sept 27th! We will Multiply Your Impact through our exciting program and social media!💥Join us in Seattle! #AM25IMPACT#gyncsm
Remember the incredible abstracts presented at the SGO 2024 Annual Meeting on Women’s Cancer?
If you're interested in presenting in 2025, SGO is now accepting abstract and surgical film submissions for the 2025 Annual Meeting. #SGOMtg#AM25IMPACT
Submit: sgo.org/events/annual-meetin…
People with advanced #EndometrialCancer now have new FDA-approved treatment options: pembrolizumab and durvalumab, paired with chemotherapy, for tumors with a genetic change called mismatch repair deficiency. go.nih.gov/Qmz5ojG
ALT A depiction of immune cells attacking cancer cells.
Rates of new #UterineCancer cases increased by 0.7% each year from 2012 to 2021. The death rate from uterine cancer increased by 1.5% each year from 2013 to 2022. Visit our Cancer Stat Facts sheet to learn more: buff.ly/2YXE2S4#GynCSM
From medical enigma to a roadmap for recovery, one @OHSUNews patient's life-altering journey through a rare skin, musculature condition and stage 3 cancer.
This is Kathy's remarkable story: bit.ly/4b2Exhx
Ever wonder why your insurer charges a copay for statins (and other high-value meds)?
Don’t they want to prevent heart attacks, strokes, etc?
Copays never made sense to me.
In this new paper in @QJEHarvard, we show copays kill. 🧵
tinyurl.com/nhk4v93f
Dear members of @sgo, a question came up during our journal club and I cannot find the answer. Can someone please help?
Why did investigators in the RUBY trial pick 3 years of Dostarlimab maintenance? Is there a biologic explanation? @matthewapowell#endometrialcancer